Dr. Kassem Bourgi, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 133
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
TN license 71966 · IN license 01080959A -
Internal Medicine Physician
MI license 4301100453 · TN license 71966
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Joseph Regional Medical Center Mishawaka, IN
Medical groups
- Saint Joseph Regional Medical Center Inc (138 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 133
- Services billed
- 296
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 51 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 44 | 19 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 31 | 30 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 40 payments worth $3,989 in total to this clinician.
| Gilead Sciences, Inc. | $2,255 |
|---|---|
| Viiv Healthcare Company | $1,702 |
| AbbVie Inc. | $32.82 |
| Consulting Fee | $1,750 |
|---|---|
| Food and Beverage | $1,162 |
| Travel and Lodging | $1,078 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Feb 11, 2025 | Consulting FeeCompany’s description;4296462;GTF;11310647 | $1,750 |
| Viiv Healthcare Company Mar 19, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $498 |
| Viiv Healthcare Company Nov 4, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $250 |
| Viiv Healthcare Company Apr 3, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $205 |
| Viiv Healthcare Company Apr 4, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $51.98 |
| Viiv Healthcare Company Oct 7, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $42.18 |
| Viiv Healthcare Company Mar 19, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $50,224 in research payments for these studies, mostly to the institutions running them.
- Reexamining The Effects of Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide on Weight Gain in the United States and Canada
Gilead Sciences, Inc. - A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US)
Theratechnologies Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.